Survivorship in Multiple Myeloma Patients Treated with CAR T-Cell Therapy
Official title: Survivorship in Patients with Multiple Myeloma Treated with Chimeric Antigen Receptor T-cell Therapy
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-11400064 · Data updated 2026-11-12
This study looks at real-world experiences and well-being of people with multiple myeloma who received CAR T-cell therapy, focusing on their symptoms, mood, and quality of life.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $2,068,249 |
| NIH project number | 4R01CA281756-03 |
| Project ID | NIH-11400064 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with multiple myeloma who have received CAR T-cell therapy and are treated at participating centers.
✕Less likely to help
Patients who have not received CAR T therapy or who are not in survivorship stages may not directly benefit.
What this research studies
Researchers will follow a real-world group of multiple myeloma patients who have received CAR T-cell therapy at Moffitt Cancer Center to see how they fare over time. They will collect blood samples and bone marrow information alongside surveys about fatigue, anxiety, depression, and social support, plus patient-reported outcomes related to quality of life. The study uses an evidence-based framework to link immune and psychosocial factors with survivorship outcomes. Findings could help clinicians tailor supportive care and track factors that influence recovery and long-term well-being after CAR T therapy.
Why it matters
Potential benefit: If successful, the study could lead to better understanding of what helps patients feel better after CAR T therapy and inform personalized survivorship care.
How similar studies have gone: Prior trials show strong responses to CAR T therapy, but this real-world survivorship study is among the first to link psychosocial and immune factors with outcomes.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Oswald, Laura B. — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Oswald, Laura B.
Related research
Other NIH-funded projects on the same topics.
-
Life after CAR T for multiple myeloma
This project will follow people with relapsed or refractory multiple myeloma who received CAR T to learn about their symptoms, quality of life, and immune changes after treatment.
-
Understanding the experiences of multiple myeloma patients treated with CAR T-cell therapy
This study is looking at how patients with relapsed or hard-to-treat multiple myeloma feel and do after receiving CAR T-cell therapy, aiming to understand their health and emotional well-being to help improve their care.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
-
How LDL Affects Multiple Myeloma: New Pathways to Keep Remission
A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.
-
Therapy-induced senescence and immune activation in multiple myeloma
A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.